Microbot Medical Appoints Dr. Juan Diaz-Cartelle as CMO

November 21, 2023—Microbot Medical Inc., developer of the Liberty endovascular robotic surgical system, announced the appointment of Juan Diaz-Cartelle, MD, as Chief Medical Officer (CMO), effective December 1, 2023.

Dr. Diaz-Cartelle succeeds Eyal Morag, MD, who was based in Israel and played an integral part of the development and testing of the Liberty system from its inception phase.

The hiring of Dr. Diaz-Cartelle, who is a based in the United States, coincides with the company’s transition from focusing mainly on research and development in Israel to its increasing United States-based activities, which include planned clinical trials for the Liberty system, the FDA regulatory process, and establishing commercial foundations to enter the United States market.

Before joining the Microbot, Dr. Diaz-Cartelle served as the Executive Medical Director at Haemonetics Corporation. For 14 years, Dr. Diaz-Cartelle was Senior Medical Director for the Peripheral Interventional Division (Endovascular and Interventional Oncology) at Boston Scientific Corporation. Previous to his corporate career, he was a research scientist at New York University in New York, New York.

“We are fortunate to have Dr. Diaz-Cartelle join our team, especially with his extensive experience in the endovascular and interventional space,” commented Harel Gadot, Chairman, President & CEO of Microbot Medical, in the company’s press release. “Dr. Diaz-Cartelle’s appointment is a testament to our commitment to excellence in our transition to the clinical and regulatory phase, especially as we are approaching our investigational device exemption submission and our upcoming clinical trial in the United States. His deep knowledge in clinical trial management, as well as leading medical affairs activities, will be invaluable as we work towards FDA clearance and continue to set new standards in robotic surgery.”

Dr. Diaz-Cartelle added, “I’m thrilled to join Microbot at this stage, as through my career, and especially over the past few years, I became a true believer in the role of robotics in the endovascular space. I’m looking forward to being part of the team that supports the clinical trials and eventually the commercialization of the Liberty system, and to bring added value to physicians, patients, and healthcare systems globally.”